CaDAnCe-302: a phase 3 trial testing the treatment BGB-16673 in adults with CLL/SLL who have previously had a BTK and BCL2 inhibitor.

This trial aims to test the effectiveness of the treatment BGB-16673 in people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have previously been treated with a BTK and BCL2 inhibitor.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06846671

Trial aim and background 

The aim of this trial is to compare the effectiveness and safety of the treatment BGB-16673 in people with CLL/SLL against the investigator’s choice of:

  • Idelalisib plus rituximab (in CLL only)
  • Bendamustine plus rituximab
  • Venetoclax plus rituximab

Investigators hope to compare the length of time people live without their CLL/SLL worsening. 

Who can enter

Adults with CLL or SLL who have previously received treatment with a BTKi and a BCL2i may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • Aberdeen Royal Infirmary, Aberdeen
  • Birmingham Heartlands Hospital, Birmingham
  • Royal Marsden Hospital, London
  • Southampton General Hospital, Southampton
  • The Royal Bournemouth and Christchurch Hospitals NHS Foundation, Bournemouth
  • University College Hospital, London.

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:

https://clinicaltrials.gov/study/NCT06846671

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.